Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- NCT06922591 ↗
- Recruiting
- Tango Therapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT06922591 (TNG462, RMC-9805 and 3 more in PDAC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06922591 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC; RAS Mutation; MTAP Deletion; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer
- Interventions
- TNG462; RMC-9805; RMC-6236; mFOLFIRINOX; gemcitabine/nab-paclitaxel
- Arms
- Dose Escalation 1A · Experimental
- Dose escalation 1B · Experimental
- Dose Expansion 2A · Experimental
- Dose Expansion 2B · Experimental
- Experimental: Dose Escalation 1C · Experimental
- Experimental: Dose Escalation 1D · Experimental
- Experimental: Dose Expansion 2C · Experimental
- Experimental: Dose Expansion 2D · Experimental
- Enrollment
- 183 (estimated)
- Primary outcomes
- Phase 1: Maximum Tolerated Dose
- Phase 1: Maximum Tolerated Dose
- Phase 2: Combination Anti-neoplastic Activity
- Sponsor
- Tango Therapeutics, Inc. with Revolution Medicines, Inc.
- Start
- May 31, 2025
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06922591 · updated Oct 23, 2026